Regulators of mitochondrial complex I activity: A review of literature and evaluation in postmortem prefrontal cortex from patients with bipolar disorder

Psychiatry Research

Volumn 236, Issue , 2016, Pages 148-157

  Duong, Angela ^a   Che, Yi ^a   Ceylan, Deniz ^c   Pinguelo, Arsene ^a   Andreazza, Ana C ^a,b   Trevor Young, L ^a,b   Berk, Michael ^d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c Psychiatry Clinic Gümü hane State Hospital   (Turkey)

^d DEAKIN UNIVERSITY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bipolar disorder; DJ 1; Gene expression; Microarray; Mitochondrial complex I; Mitochondrial regulators

Indexed keywords

DJ 1 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SIRTUIN 3; STAT3 PROTEIN; IGF2BP2 PROTEIN, HUMAN; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; PROTEIN DEGLYCASE DJ-1; RNA BINDING PROTEIN; SIGNAL PEPTIDE; SIRT3 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

AGE; ARTICLE; AUTOPSY; BIPOLAR DISORDER; DOWN REGULATION; ENZYME REGULATION; GENE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMP 2 GENE; MICROARRAY ANALYSIS; PARK 7 GENE; PREFRONTAL CORTEX; PRIORITY JOURNAL; SIRT 3 GENE; STAT 3 GENE; VALIDATION STUDY; ADULT; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; UPREGULATION; VERY ELDERLY;

ADULT; AGED, 80 AND OVER; AUTOPSY; BIPOLAR DISORDER; DOWN-REGULATION; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; ONCOGENE PROTEINS; PREFRONTAL CORTEX; PROTEIN DEGLYCASE DJ-1; RNA-BINDING PROTEINS; SIRTUIN 3; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84957683514     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.12.015     Document Type: Article

References (122)

1. Ahn B.H., Kim H.S., Song S., Lee I.H., Liu J., Vassilopoulos A., Deng C.X., Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14447-14452.
2. Alberio T., Mammucari C., D'Agostino G., Rizzuto R., Fasano M. Altered dopamine homeostasis differentially affects mitochondrial voltage-dependent anion channels turnover. Biochim. Biophys. Acta 2014, 1842:1816-1822.
3. Anderson I.M., Haddad P.M., Scott J. Bipolar disorder. Br. Med. J. 2012, 345:e8508.
4. Andreazza A.C., Shao L., Wang J.F., Young L.T. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch. Gen. Psychiatry 2010, 67:360-368.
5. Andreazza A.C., Young L.T. The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. Int. J. Neuropsychopharmacol. 2014, 17:1039-1052.
6. Ashley A.K., Hanneman W.H., Katoh T., Moreno J.A., Pollack A., Tjalkens R.B., Legare M.E. Analysis of targeted mutation in DJ-1 on cellular function in primary astrocytes. Toxicol. Lett. 2009, 184:186-191.
7. Balijepalli S., Kenchappa R.S., Boyd M.R., Ravindranath V. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem. Int. 2001, 38:425-435.
8. Bandopadhyay R., Kingsbury A.E., Cookson M.R., Reid A.R., Evans I.M., Hope A.D., Pittman A.M., Lashley T., Canet-Aviles R., Miller D.W., McLendon C., Strand C., Leonard A.J., Abou-Sleiman P.M., Healy D.G., Ariga H., Wood N.W., de Silva R., Revesz T., Hardy J.A., Lees A.J. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004, 127:420-430.
9. Bause A.S., Haigis M.C. SIRT3 regulation of mitochondrial oxidative stress. Exp. Gerontol. 2013, 48:634-639.
10. Beal M.F. Oxidatively modified proteins in aging and disease. Free. Radic. Biol. Med. 2002, 32:797-803.
11. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 1996, 271:C1424-C1437.
12. Beer S.M., Taylor E.R., Brown S.E., Dahm C.C., Costa N.J., Runswick M.J., Murphy M.P. Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins: implications for mitochondrial redox regulation and antioxidant DEFENSE. J. Biol. Chem. 2004, 279:47939-47951.
13. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 1991, 56:1441-1444.
14. Ben-Shachar D., Zuk R., Gazawi H., Ljubuncic P. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem. Pharmacol. 2004, 67:1965-1974.
15. Berk M., Dodd S., Kauer-Sant'anna M., Malhi G.S., Bourin M., Kapczinski F., Norman T. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl. 2007, 434:41-49.
16. Berk M., Nierenberg A.A. Three paths to drug discovery in psychiatry. Am. J. Psychiatry 2015, 172:412-414.
17. Bharath S., Andersen J.K. Glutathione depletion in a midbrain-derived immortalized dopaminergic cell line results in limited tyrosine nitration of mitochondrial complex I subunits: implications for Parkinson's disease. Antioxid. Redox Signal 2005, 7:900-910.
18. Blackinton J., Kumaran R., van der Brug M.P., Ahmad R., Olson L., Galter D., Lees A., Bandopadhyay R., Cookson M.R. Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease. Neurosci. Lett. 2009, 452:8-11.
19. Borutaite V., Brown G.C. S-nitrosothiol inhibition of mitochondrial complex I causes a reversible increase in mitochondrial hydrogen peroxide production. Biochim. Biophys. Acta 2006, 1757:562-566.
20. Brown G.C., Borutaite V. Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim. Biophys. Acta 2004, 1658:44-49.
21. Brown N.C., Andreazza A.C., Young L.T. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014, 218:61-68.
22. Calkin C.V., Gardner D.M., Ransom T., Alda M. The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders. Ann. Med. 2013, 45:171-181.
23. Callaly E., Walder K., Morris G., Maes M., Debnath M., Berk M. Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy. Mini Rev. Med. Chem. 2015, 15:355-365.
24. Cannino G., El-Khoury R., Pirinen M., Hutz B., Rustin P., Jacobs H.T., Dufour E. Glucose modulates respiratory complex I activity in response to acute mitochondrial dysfunction. J. Biol. Chem. 2012, 287:38729-38740.
25. Chang M.C., Contreras M.A., Rosenberger T.A., Rintala J.J., Bell J.M., Rapoport S.I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J. Neurochem. 2001, 77:796-803.
26. Chinta S.J., Andersen J.K. Nitrosylation and nitration of mitochondrial complex I in Parkinson's disease. Free. Radic. Res. 2011, 45:53-58.
27. Chinta S.J., Andersen J.K. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free. Radic. Biol. Med. 2006, 41:1442-1448.
28. Chinta S.J., Kumar J.M., Zhang H., Forman H.J., Andersen J.K. Up-regulation of gamma-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson's disease. Free. Radic. Biol. Med. 2006, 40:1557-1563.
29. Chinta S.J., Kumar M.J., Hsu M., Rajagopalan S., Kaur D., Rane A., Nicholls D.G., Choi J., Andersen J.K. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J. Neurosci. 2007, 27:13997-14006.
30. Choi K.H., Elashoff M., Higgs B.W., Song J., Kim S., Sabunciyan S., Diglisic S., Yolken R.H., Knable M.B., Torrey E.F., Webster M.J. Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays. BMC Psychiatry 2008, 8:87. 244X-8-87.
31. Choi D.Y., Liu M., Hunter R.L., Cass W.A., Pandya J.D., Sullivan P.G., Shin E.J., Kim H.C., Gash D.M., Bing G. Striatal neuroinflammation promotes Parkinsonism in rats. PLOS One 2009, 4:e5482.
32. Clay H.B., Sillivan S., Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int. J. Dev. Neurosci. 2011, 29:311-324.
33. Clementi E., Brown G.C., Feelisch M., Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7631-7636.
34. Cocco T., Di Paola M., Papa S., Lorusso M. Arachidonic acid interaction with the mitochondrial electron transport chain promotes reactive oxygen species generation. Free. Radic. Biol. Med. 1999, 27:51-59.
35. Dabbeni-Sala F., Di Santo S., Franceschini D., Skaper S.D., Giusti P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J. 2001, 15:164-170.
36. Davis C.W., Hawkins B.J., Ramasamy S., Irrinki K.M., Cameron B.A., Islam K., Daswani V.P., Doonan P.J., Manevich Y., Madesh M. Nitration of the mitochondrial complex I subunit NDUFB8 elicits RIP1- and RIP3-mediated necrosis. Free. Radic. Biol. Med. 2010, 48:306-317.
37. Dell'Osso B., Ketter T.A., Cremaschi L., Spagnolin G., Altamura A.C. Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression. Curr. Psychiatry Rep. 2013, 15. 378-013-0378-z.
38. Elschami M., Scherr M., Philippens B., Gerardy-Schahn R. Reduction of STAT3 expression induces mitochondrial dysfunction and autophagy in cardiac HL-1 cells. Eur. J. Cell. Biol. 2013, 92:21-29.
39. Frey B.N., Dias R.S. Sex hormones and biomarkers of neuroprotection and neurodegeneration: implications for female reproductive events in bipolar disorder. Bipolar Disord. 2014, 16:48-57.
40. Fujii Y., Kishi Y., Gotoh Y. IMP2 regulates differentiation potentials of mouse neocortical neural precursor cells. Genes. Cells 2013, 18:79-89.
41. Gao H., Yang W., Qi Z., Lu L., Duan C., Zhao C., Yang H. DJ-1 protects dopaminergic neurons against rotenone-induced apoptosis by enhancing ERK-dependent mitophagy. J. Mol. Biol. 2012, 423:232-248.
42. Gigante A.D., Young L.T., Yatham L.N., Andreazza A.C., Nery F.G., Grinberg L.T., Heinsen H., Lafer B. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. Int. J. Neuropsychopharmacol. 2011, 14:1075-1089.
43. Glinka Y., Tipton K.F., Youdim M.B. Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur. J. Pharmacol. 1998, 351:121-129.
44. Glinka Y., Tipton K.F., Youdim M.B. Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J. Neurochem. 1996, 66:2004-2010.
45. Glinka Y.Y., Youdim M.B. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 1995, 292:329-332.
46. Gough D.J., Corlett A., Schlessinger K., Wegrzyn J., Larner A.C., Levy D.E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-1716.
47. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 1978, 14:633-643.
48. Haigang R., Kai F., Jun F., Guanghui W. The role of DJ-1 in anti-apoptosis. Mol. Neurodegener. 2012, 7.
49. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 1992, 59:1609-1623.
50. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:1956-1961.
51. Hayashi T., Ishimori C., Takahashi-Niki K., Taira T., Kim Y.C., Maita H., Maita C., Ariga H., Iguchi-Ariga S.M. DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem. Biophys. Res. Commun. 2009, 390:667-672.
52. Heales S.J., Bolanos J.P. Impairment of brain mitochondrial function by reactive nitrogen species: the role of glutathione in dictating susceptibility. Neurochem. Int. 2002, 40:469-474.
53. Hirst J. Mitochondrial complex I. Annu. Rev. Biochem. 2013, 82:551-575.
54. Hsu M., Srinivas B., Kumar J., Subramanian R., Andersen J. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. J. Neurochem. 2005, 92:1091-1103.
55. Iglesias-Gonzalez J., Sanchez-Iglesias S., Mendez-Alvarez E., Rose S., Hikima A., Jenner P., Soto-Otero R. Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase. Neurochem. Res. 2012, 37:2150-2160.
56. Inden M., Taira T., Kitamura Y., Yanagida T., Tsuchiya D., Takata K., Yanagisawa D., Nishimura K., Taniguchi T., Kiso Y., Yoshimoto K., Agatsuma T., Koide-Yoshida S., Iguchi-Ariga S.M., Shimohama S., Ariga H. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol. Dis. 2006, 24:144-158.
57. Jain A., Martensson J., Stole E., Auld P.A., Meister A. Glutathione deficiency leads to mitochondrial damage in brain. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:1913-1917.
58. Jana S., Maiti A.K., Bagh M.B., Banerjee K., Das A., Roy A., Chakrabarti S. Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson's disease. Brain Res. 2007, 1139:195-200.
59. Jana S., Sinha M., Chanda D., Roy T., Banerjee K., Munshi S., Patro B.S., Chakrabarti S. Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: Implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease. Biochim. Biophys. Acta 2011, 1812:663-673.
60. Janiszewska M., Suva M.L., Riggi N., Houtkooper R.H., Auwerx J., Clement-Schatlo V., Radovanovic I., Rheinbay E., Provero P., Stamenkovic I. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes. Dev. 2012, 26:1926-1944.
61. Jha N., Jurma O., Lalli G., Liu Y., Pettus E.H., Greenamyre J.T., Liu R.M., Forman H.J., Andersen J.K. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J. Biol. Chem. 2000, 275:26096-26101.
62. Jones D.P., Mody V.C., Carlson J.L., Lynn M.J., Sternberg P. Redox analysis of human plasma allows separation of pro-oxidant events of aging from decline in antioxidant defenses. Free. Radic. Biol. Med. 2002, 33:1290-1300.
63. Karunakaran S., Saeed U., Ramakrishnan S., Koumar R.C., Ravindranath V. Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain. Brain Res. 2007, 1185:8-17.
64. Kato T., Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2000, 2:180-190.
65. Khan F.H., Sen T., Maiti A.K., Jana S., Chatterjee U., Chakrabarti S. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. Biochim. Biophys. Acta 2005, 1741:65-74.
66. Kim R.H., Smith P.D., Aleyasin H., Hayley S., Mount M.P., Pownall S., Wakeham A., You-Ten A.J., Kalia S.K., Horne P., Westaway D., Lozano A.M., Anisman H., Park D.S., Mak T.W. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:5215-5220.
67. Kim Y.H., Rane A., Lussier S., Andersen J.K. Lithium protects against oxidative stress-mediated cell death in alpha-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease. J. Neurosci. Res. 2011, 89:1666-1675.
68. Kong X., Wang R., Xue Y., Liu X., Zhang H., Chen Y., Fang F., Chang Y. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLOS One 2010, 5:e11707.
69. Kulkarni J., Berk M., Wang W., Mu L., Scarr E., Van Rheenen T.E., Worsley R., Gurvich C., Gavrilidis E., de Castella A., Fitzgerald P., Davis S.R. A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. Psychoneuroendocrinology 2014, 43:52-61.
70. Kulkarni J., Gavrilidis E., Wang W., Worsley R., Fitzgerald P.B., Gurvich C., Van Rheenen T., Berk M., Burger H. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol. Psychiatry 2015, 20:695-702.
71. Kulkarni J., Gurvich C., Lee S.J., Gilbert H., Gavrilidis E., de Castella A., Berk M., Dodd S., Fitzgerald P.B., Davis S.R. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010, 35:1142-1147.
72. Kwon H.J., Heo J.Y., Shim J.H., Park J.H., Seo K.S., Ryu M.J., Han J.S., Shong M., Son J.H., Kweon G.R. DJ-1 mediates paraquat-induced dopaminergic neuronal cell death. Toxicol. Lett. 2011, 202:85-92.
73. Lee D.W., Kaur D., Chinta S.J., Rajagopalan S., Andersen J.K. A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease. Antioxid. Redox Signal 2009, 11:2083-2094.
74. Levy D.E., Lee C.K. What does Stat3 do?. J. Clin. Invest 2002, 109:1143-1148.
75. Liochev S.I. Reactive oxygen species and the free radical theory of aging. Free. Radic. Biol. Med. 2013, 60:1-4.
76. Liu G., Zhang C., Yin J., Li X., Cheng F., Li Y., Yang H., Ueda K., Chan P., Yu S. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 2009, 454:187-192.
77. Loeb V., Yakunin E., Saada A., Sharon R. The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. J. Biol. Chem. 2010, 285:7334-7343.
78. Maker H.S., Weiss C., Silides D.J., Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem. 1981, 36:589-593.
79. Malhi G.S., Fritz K., Allwang C., Burston N., Cocks C., Harper M., Kearney B., Klug P., Meagher L., Mimnagh J., Purayil S., Rowe M., Samir H., Way R., Wilson C., Lyndon W. Agitation for recognition by DSM-5 mixed features specifier signals fatigue?. Aust. N. Z. J. Psychiatry 2015, 49:499-501.
80. Mari M., Morales A., Colell A., Garcia-Ruiz C., Fernandez-Checa J.C. Mitochondrial glutathione, a key survival antioxidant. Antioxid. Redox Signal 2009, 11:2685-2700.
81. Marla S.S., Lee J., Groves J.T. Peroxynitrite rapidly permeates phospholipid membranes. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:14243-14248.
82. Martin H.L., Teismann P. Glutathione--a review on its role and significance in Parkinson's disease. FASEB J. 2009, 23:3263-3272.
83. Maurer I., Moller H.J. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell. Biochem. 1997, 174:255-259.
84. Meinhard N., Kessing L.V., Vinberg M. The role of estrogen in bipolar disorder, a review. Nord. J. Psychiatry 2014, 68:81-87.
85. Moreira P.I., Custodio J., Moreno A., Oliveira C.R., Santos M.S. Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. J. Biol. Chem. 2006, 281:10143-10152.
86. Morris G., Anderson G., Berk M., Maes M. Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Mol. Neurobiol. 2013, 48:883-903.
87. Morris G., Berk M. The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med. 2015, 13. 68-015-0310-y.
88. Morris G., Anderson G., Dean O., Berk M., Galecki P., Martin-Subero M., Maes M. The glutathione system: a new drug target in neuroimmune disorders. Mol. Neurobiol. 2014, 50:1059-1084.
89. Moylan S., Berk M., Dean O.M., Samuni Y., Williams L.J., O'Neil A., Hayley A.C., Pasco J.A., Anderson G., Jacka F.N., Maes M. Oxidative & nitrosative stress in depression: why so much stress?. Neurosci. Biobehav. Rev. 2014, 45:46-62.
90. Mu Q., Wang L., Yu F., Gao H., Lei T., Li P., Liu P., Zheng X., Hu X., Chen Y., Jiang Z., Sayari A.J., Shen J., Huang H. Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway. Cancer. Biol. Ther. 2015, 16:623-633.
91. Mullett S.J., Hinkle D.A. DJ-1 deficiency in astrocytes selectively enhances mitochondrial Complex I inhibitor-induced neurotoxicity. J. Neurochem. 2011, 117:375-387.
92. Mullett S.J., Hinkle D.A. DJ-1 knock-down in astrocytes impairs astrocyte-mediated neuroprotection against rotenone. Neurobiol. Dis. 2009, 33:28-36.
93. Murray J., Taylor S.W., Zhang B., Ghosh S.S., Capaldi R.A. Oxidative damage to mitochondrial complex I due to peroxynitrite: identification of reactive tyrosines by mass spectrometry. J. Biol. Chem. 2003, 278:37223-37230.
94. Nagakubo D., Taira T., Kitaura H., Ikeda M., Tamai K., Iguchi-Ariga S.M., Ariga H. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun. 1997, 231:509-513.
95. Narendra D.P., Jin S.M., Tanaka A., Suen D.F., Gautier C.A., Shen J., Cookson M.R., Youle R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLOS Biol. 2010, 8:e1000298.
96. Nunes C., Barbosa R.M., Almeida L., Laranjinha J. Nitric oxide and DOPAC-induced cell death: from GSH depletion to mitochondrial energy crisis. Mol. Cell. Neurosci. 2011, 48:94-103.
97. Onorato J.M., Thorpe S.R., Baynes J.W. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann. N. Y. Acad. Sci. 1998, 854:277-290.
98. Petersen K.F., Befroy D., Dufour S., Dziura J., Ariyan C., Rothman D.L., Loretta DiPietro L., Gary W., Cline G.W., Shulman G.I. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300(5622):1140-1142.
99. Phillips D., Reilley M.J., Aponte A.M., Wang G., Boja E., Gucek M., Balaban R.S. Stoichiometry of STAT3 and mitochondrial proteins: Implications for the regulation of oxidative phosphorylation by protein-protein interactions. J. Biol. Chem. 2010, 285:23532-23536.
100. Poderoso J.J., Lisdero C., Schopfer F., Riobo N., Carreras M.C., Cadenas E., Boveris A. The regulation of mitochondrial oxygen uptake by redox reactions involving nitric oxide and ubiquinol. J. Biol. Chem. 1999, 274:37709-37716.
101. Rajasekaran A., Venkatasubramanian G., Berk M., Debnath M. Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications. Neurosci. Biobehav. Rev. 2015, 48:10-21.
102. Ramachandran A., Ceaser E., Darley-Usmar V.M. Chronic exposure to nitric oxide alters the free iron pool in endothelial cells: role of mitochondrial respiratory complexes and heat shock proteins. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:384-389.
103. Rapoport S.I., Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?. Arch. Gen. Psychiatry 2002, 59:592-596.
104. Rapoport S.I. Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chem. Neurosci. 2014, 5:459-467.
105. Remor A.P., de Matos F.J., Ghisoni K., da Silva T.L., Eidt G., Burigo M., de Bem A.F., Silveira P.C., de Leon A., Sanchez M.C., Hohl A., Glaser V., Goncalves C.A., Quincozes-Santos A., Borba Rosa R., Latini A. Differential effects of insulin on peripheral diabetes-related changes in mitochondrial bioenergetics: involvement of advanced glycosylated end products. Biochim. Biophys. Acta 2011, 1812:1460-1471.
106. Riobo N.A., Clementi E., Melani M., Boveris A., Cadenas E., Moncada S., Poderoso J.J. Nitric oxide inhibits mitochondrial NADH:ubiquinone reductase activity through peroxynitrite formation. Biochem. J. 2001, 359:139-145.
107. Rosa A.R., Singh N., Whitaker E., de Brito M., Lewis A.M., Vieta E., Churchill G.C., Geddes J.R., Goodwin G.M. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychol. Med. 2014, 1-10.
108. Sack M.N., Finkel T. Mitochondrial metabolism, sirtuins, and aging. Cold Spring Harb Perspect. Biol. 2012, 4:a013102. 10.1101/cshperspect.
109. Sai Y., Zou Z., Peng K., Dong Z. The Parkinson's disease-related genes act in mitochondrial homeostasis. Neurosci. Biobehav. Rev. 2012, 36:2034-2043.
110. Savitz J.B., Price J.L., Drevets W.C. Neuropathological and neuromorphometric abnormalities in bipolar disorder: view from the medial prefrontal cortical network. Neurosci. Biobehav. Rev. 2014, 42:132-147.
111. Scola G., Kim H.K., Young L.T., Andreazza A.C. A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. Biol. Psychiatry 2013, 73:e4-e5.
112. Sidhu A., Wersinger C., Vernier P. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?. FASEB J. 2004, 18:637-647.
113. Sugiyama C., Kuramoto N., Seko K., Yoneda Y., Ogita K. Decreased level of mitochondrial RNA by glutamate in cultured cortical neurons. Neuroreport 2007, 18:827-830.
114. Taira T., Saito Y., Niki T., Iguchi-Ariga S.M., Takahashi K., Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 2004, 5:213-218.
115. Takahashi-Niki K., Niki T., Iguchi-Ariga S., Ariga H. Function of DJ-1 in mitochondria. Yakugaku Zasshi 2012, 132:1105-1110.
116. Takeuchi Y., Morii H., Tamura M., Hayaishi O., Watanabe Y. A possible mechanism of mitochondrial dysfunction during cerebral ischemia: inhibition of mitochondrial respiration activity by arachidonic acid. Arch. Biochem. Biophys. 1991, 289:33-38.
117. Taylor E.R., Hurrell F., Shannon R.J., Lin T.K., Hirst J., Murphy M.P. Reversible glutathionylation of complex I increases mitochondrial superoxide formation. J. Biol. Chem. 2003, 278:19603-19610.
118. Torrey E.F., Webster M., Knable M., Johnston N., Yolken R.H. The stanley foundation brain collection and neuropathology consortium. Schizophr. Res. 2000, 44:151-155.
119. Wegrzyn J., Potla R., Chwae Y.J., Sepuri N.B., Zhang Q., Koeck T., Derecka M., Szczepanek K., Szelag M., Gornicka A., Moh A., Moghaddas S., Chen Q., Bobbili S., Cichy J., Dulak J., Baker D.P., Wolfman A., Stuehr D., Hassan M.O., Fu X.Y., Avadhani N., Drake J.I., Fawcett P., Lesnefsky E.J., Larner A.C. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:793-797.
120. Weir H.J., Lane J.D., Balthasar N. SIRT3: A Central Regulator of Mitochondrial Adaptation in Health and Disease. Genes. Cancer 2013, 4:118-124.
121. Woods S.W. The economic burden of bipolar disease. J. Clin. Psychiatry 2000, 61(Supp 13):38-41.
122. Yamamoto T., Maruyama W., Kato Y., Yi H., Shamoto-Nagai M., Tanaka M., Sato Y., Naoi M. Selective nitration of mitochondrial complex I by peroxynitrite: involvement in mitochondria dysfunction and cell death of dopaminergic SH-SY5Y cells. J. Neural Transm. 2002, 109:1-13.